{"url_path":"/sec/fenc/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1211583/0001104659-26-061213-index.html","accession_number":"0001104659-26-061213","cik":"0001211583","ticker":"FENC","issuer_name":"FENNEC PHARMACEUTICALS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1211583/0001104659-26-061213-index.html","primary_entity_key":"0001211583","primary_entity_name":"FENNEC PHARMACEUTICALS INC."},"word_count":305,"has_tables":true,"body_markdown":"**Item 6. Exhibits**\n\n​\n\n**Exhibit**\n**No.**\n\n  ​ ​ ​\n\n**Description**\n\n10.1*\n\n​\n\n[Fennec Pharmaceuticals Inc. 2026 Equity Inducement Plan (incorporated herein by reference to Schedule B to the Management Proxy Circular of the Company filed April 28, 2026).](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001211583/000110465926050339/fencf-20260610xdef14a.htm)\n\n​\n\n31.1\n\n​\n\n[Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).](fencf-20260331xex31d1.htm)\n\n \n\n​\n\n \n\n31.2\n\n​\n\n[Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).](fencf-20260331xex31d2.htm)\n\n \n\n​\n\n \n\n32.1\n\n​\n\n[Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).](fencf-20260331xex32d1.htm)\n\n \n\n​\n\n \n\n99.1\n\n​\n\n[Press Release for Quarter Ended March 31, 2026 (filed herewith).](fencf-20260331xex99d1.htm)\n\n \n\n​\n\n \n\n101.INS\n\n​\n\nInline XBRL Instance Document\n\n​\n\n​\n\n​\n\n101.SCH\n\n​\n\nInline XBRL Taxonomy Extension Schema Document\n\n​\n\n​\n\n​\n\n101.CAL\n\n​\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n​\n\n​\n\n​\n\n101.DEF\n\n​\n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n​\n\n​\n\n​\n\n101.LAB\n\n​\n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n​\n\n​\n\n​\n\n101.PRE\n\n​\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension\n\ninformation contained in Exhibits 101)\n\n​\n\n* Indicates a management contract or compensatory plan.\n\n​\n\n31\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\n​\n\nPursuant to requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n \n\nFennec Pharmaceuticals Inc.\n\n \n\n \n\n \n\nDate: May 14, 2026\n\nBy:\n\n*/s/ Jeffrey Hackman*\n\n \n\n \n\nJeffrey Hackman\n\n \n\n \n\nChief Executive Officer\n\n \n\n \n\n(principal executive officer)\n\n \n\n \n\n \n\nDate: May 14, 2026\n\nBy:\n\n*/s/ Robert Andrade*\n\n \n\n \n\nRobert Andrade\n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n(principal financial and chief accounting officer)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n32"}